Service d'Endocrinologie, Diabétologie, Maladies Métaboliques, CHU Dijon, Dijon, France; INSERM, LNC-UMR 1231, Université de Bourgogne, Dijon, France.
Service d'Endocrinologie, Diabétologie, Maladies Métaboliques, CHU Dijon, Dijon, France; INSERM, LNC-UMR 1231, Université de Bourgogne, Dijon, France.
Diabetes Metab. 2023 May;49(3):101432. doi: 10.1016/j.diabet.2023.101432. Epub 2023 Feb 11.
Nonalcoholic fatty liver disease (NAFLD) encompasses simple liver steatosis, nonalcoholic steatohepatitis (NASH), and liver fibrosis that can progress to cirrhosis. NAFLD has become the principal cause of chronic liver disease in many parts of the world. Lipidomic studies, by allowing to determine concentrations of lipid classes and fatty acid composition of different lipid species, have been of great interest to help understand NAFLD pathophysiology and potentially identify novel biomarkers for diagnosis and prognosis. Indeed, lipidomic data give information on qualitative lipid abnormalities associated with NAFLD. The aim of our article was to create a comprehensive and more synthetic review of main results from lipidomic studies in NAFLD. Literature was searched for all human lipidomic studies evaluating plasma samples of individuals with NAFLD. Results were regrouped by the degree of liver damage, either simple steatosis, NASH or liver fibrosis, and presented by lipid categories. Overall, we summarized the main lipidomic abnormalities associated with NAFLD as follows: modification of free fatty acid distribution, increase in ceramides, reduced phosphatidylcholine / phosphatidylethanolamine ratio, and increase in eicosanoids. These lipid abnormalities are likely to promote NASH and liver fibrosis by inducing mitochondrial dysfunction, apoptosis, inflammation, oxidation, and endoplasmic reticulum stress. Although these lipidomic abnormalities are consistently reported in many studies, further research is needed to clarify whether they may be predictive for liver steatosis, NASH or liver fibrosis.
非酒精性脂肪性肝病(NAFLD)包括单纯性肝脂肪变性、非酒精性脂肪性肝炎(NASH)和肝纤维化,这些疾病可进展为肝硬化。NAFLD 已成为世界许多地区慢性肝病的主要原因。脂质组学研究通过确定不同脂质种类的脂质类和脂肪酸组成的浓度,对于帮助理解 NAFLD 的病理生理学并可能确定用于诊断和预后的新型生物标志物非常有意义。实际上,脂质组学数据提供了与 NAFLD 相关的定性脂质异常的信息。本文的目的是综合和更全面地综述 NAFLD 的脂质组学研究的主要结果。对评估 NAFLD 个体血浆样本的人类脂质组学研究进行了文献检索。根据肝损伤的程度(单纯性脂肪变性、NASH 或肝纤维化)将结果进行分组,并按脂质类别进行呈现。总的来说,我们将与 NAFLD 相关的主要脂质组学异常概括如下:游离脂肪酸分布的改变、神经酰胺增加、磷脂酰胆碱/磷脂酰乙醇胺比值降低以及类二十烷酸增加。这些脂质异常可能通过诱导线粒体功能障碍、细胞凋亡、炎症、氧化和内质网应激来促进 NASH 和肝纤维化的发生。尽管这些脂质异常在许多研究中得到了一致的报道,但仍需要进一步的研究来阐明它们是否可用于预测肝脂肪变性、NASH 或肝纤维化。